ReviewJournal of hematology & oncology2012
Therapeutic advancement of chronic lymphocytic leukemia.
Review in Journal of hematology & oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Targeting metabolic reprogramming in chronic lymphocytic leukemia.Experimental hematology & oncology · 2022Review
- Prognostic and Therapeutic Value of Apolipoprotein A and a New Risk Scoring System Based on Apolipoprotein A and Adenosine Deaminase in Chronic Lymphocytic Leukemia.Frontiers in oncology · 2021Article
- Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia.Biomarker research · 2020Review
- STAT3 promotes chronic lymphocytic leukemia progression through upregulating SMYD3 expression.Archives of medical science : AMS · 2019Article
- STAT6 phosphorylation upregulates microRNA-155 expression and subsequently enhances the pathogenesis of chronic lymphocytic leukemia.Oncology letters · 2019Article
- A Comparison of Cytotoxic Effects ofIranian journal of pharmaceutical research : IJPR · 2019Article
- Ellagic acid, a polyphenolic compound, selectively induces ROS-mediated apoptosis in cancerous B-lymphocytes of CLL patients by directly targeting mitochondria.Redox biology · 2015Article
- Metadherin contributes to the pathogenesis of chronic lymphocytic leukemia partially through Wnt/β-catenin pathway.Medical oncology (Northwood, London, England) · 2015Article
- Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.Journal of hematology & oncology · 2014Review
- Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock.Frontiers of medicine · 2014Article
- Ibrutinib for B cell malignancies.Experimental hematology & oncology · 2014Article
- Role of high expression of IL-9 in prognosis of CLL.International journal of clinical and experimental pathology · 2014Article
- SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway.BioMed research international · 2014Article
- Fludarabine downregulates indoleamine 2,3-dioxygenase in tumors via a proteasome-mediated degradation mechanism.PloS one · 2014Article
- STAT inhibitors for cancer therapy.Journal of hematology & oncology · 2013Review
- Resistance to Dasatinib in primary chronic lymphocytic leukemia lymphocytes involves AMPK-mediated energetic re-programming.Oncotarget · 2013Article
- Clinical development of phosphatidylinositol 3-kinase inhibitors for non-Hodgkin lymphoma.Biomarker research · 2013Article
- Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.Journal of hematology & oncology · 2013Article
- The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.Journal of hematology & oncology · 2013Review
- Ibrutinib and novel BTK inhibitors in clinical development.Journal of hematology & oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the combinations of chemotherapy with monoclonal antibodies have further improved response rates, chronic lymphocytic leukemia (CLL) remains an incurable disease with an extremely variable course. This article reviews the ongoing clinical advances in the treatment of CLL in both previously untreated and relapsed disease and focuses on the benefit of different therapeutic strategies, the most effective therapy combinations and the potential activity of novel agents. Novel agents and combination therapies have been investigated by several studies in both the upfront and relapsed setting, particularly for patients with 17p deletion, TP53 mutation and fludarabine-refractory CLL. While these agents and combination therapies have improved initial response rates, ongoing studies are continued to determine and improve the efficacy and safety. Despite advancements in the treatment of CLL have led to high response rates, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative option and reduced-intensity conditioning (RIC) allo-HSCT must be strongly considered whenever feasible. As such, ongoing studies of these agents and other novel approaches in clinical development are needed to expand and improve treatment options for CLL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.